NCT05268926View on ClinicalTrials.gov

TreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertension

PHASE2TerminatedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

February 3, 2022

Primary Completion Date

February 2, 2023

Study Completion Date

February 2, 2023

Conditions

Albuminuria

Interventions

DRUG

Dapagliflozin 10Mg Tab

dapagliflozin 10 mg/d or matched placebo

DRUG

Placebo

Placebo

Trial Locations (1)

Unknown

UMCG, Groningen

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

University Medical Center Groningen

OTHER